Quanome Technologies To Acquire 5% Stake In QAI Labs Through All-Stock Strategic Investment Agreement

All-stock transactions will give Quanome approximately 5% stake in QAI Labs, the developer of NOVA-3, an AI-enabled platform designed for multi-specific antibody discovery

New York, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (NASDAQ:QNME) ("Quanome" or the "Company") today announced that it has entered into a definitive agreement, dated November 4, 2026, for its strategic investment in QAI Labs Ltd. ("QAI Labs" or "QAI"), an early-stage life sciences technology company developing NOVA-3, an AI-enabled discovery platform designed to combine quantum-computing algorithms (run on classical simulators) with laboratory testing to advance multi-specific antibody candidates. Under the all-stock transaction, QAI Labs will issue at closing 31,579 new shares to Quanome, representing approximately 5% equity interest in QAI Labs immediately after the issuance. In exchange, Quanome will issue at closing 6,541,236 new shares of its common stock to QAI Labs, equal to approximately 19% of Quanome's outstanding common stock immediately before the issuance, and approximately 15.97% immediately after the issuance. Closing is subject to customary closing conditions.

The proposed investment may advance Quanome's Quantum Life Sciences - Molecular Discovery stream, one of the Company's four targeted strategic pillars for applying quantum science and artificial intelligence to high-value industry challenges. QAI Labs brings together a digital discovery platform, a quantum-computing algorithm program (run on classical simulators) and laboratory research capability in Sugar Land, Texas.

QAI Labs' NOVA-3 platform is designed to use AI to assemble and rank multi-specific antibody candidates before laboratory work begins. According to information provided by QAI, its curated library includes antibody building-block pairs, which may support the evaluation of a broad range of potential molecular combinations. Its research program is exploring how quantum-enhanced methods may assist selected complex calculations and optimization problems, with laboratory results designed to feed back into each new molecule design cycle. This integrated loop is intended to help prioritize candidates for laboratory evaluation and improve the allocation of research resources. QAI Labs remains at an early, pre-commercial stage, with all molecule candidates require laboratory validation, clinical development and regulatory approval before potential commercialization.